ReachMD CME

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-gdmt-isnt-enough-understanding-residual-risk-in-patients-with-hfref/51036/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findi...

CME credits: 0.25 Valid until: 10-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/ Contemporary trial data and global registries consistently show that ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event still carry residual risk...

CME credits: 0.25 Valid until: 10-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-b7-h3-in-es-sclc-advancing-targeted-therapy-through-evidence-based-innovation-and-multidisciplinary-care/36232/ This online educational activity reviews the scientific rationale for B7-H3 as a therapeutic target in extensive-stage small cell lung cancer (ES-SCLC). Tune in for recent clinic...

CME credits: 1.00 Valid until: 08-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-best-practice-in-diagnosis-and-management-of-systemic-mastocytosis/54694/ On-demand webcast featuring expert-informed best practices for diagnosing and managing patients with systemic mastocytosis (SM) as well as the latest data on new and emerging SM thera...

CME credits: 1.00 Valid until: 05-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/early-clues-lasting-impact-detecting-and-treating-alzheimers-disease-in-its-earliest-stages/56389/ Watch this webcast exploring the evolving landscape of early Alzheimer’s disease (AD) detection and treatment and highlighting the role of cognitive screening, fluid biomarkers, and emerging therapies....

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/ This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bis...

CME credits: 0.50 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/ This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanc...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/ This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/missing-the-window-in-ambulatory-patients-with-hfref-on-gdmt-strategies-for-cv-risk-reduction/48813/ For ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event, cardiologists continue to face a major clinical challenge: persist...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/ This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetocl...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/ Dr. John Byrd discusses current and emerging strategies for managing double-class-refractory chronic lymphocytic leukemia (CLL) in community settings. He emphasizes the importance of distinguishing resistance from...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/ This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. D...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/it-takes-a-village-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37714/ In this didactic case presentation, Dr. David Eichenbaum discusses an 88-year-old patient with non-central geographic atrophy who received inappropriate bevacizumab treatment due to un...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/a-case-of-missed-diagnosis-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37713/ In this case-based presentation, Dr. Esther Lee Kim reviews a young patient with long-standing type 2 diabetes who presented with bilateral vision loss and was initially referr...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/patient-at-high-risk-of-loss-to-follow-up-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37711/ In this clinical discussion, Dr. Deepak Sambhara presents a case of a working-age man with severe non-proliferative diabetic retinopathy and diabetic macular ede...

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-cultural-and-communication-disconnects-part-of-the-focused-sight-initiative-quality-improvement-interventions-in-retinal-disease/37710/ In this case-based discussion, Dr. David Chin Yee presents his challenges and outcomes when managing a patient with diabetic macular edema who initially...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early effi...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inh...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/nsclc-data-review-efficacy-and-safety-data-for-on-state-ras-inhibitors/54121/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review ea...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanistic-evolution-in-ras-therapy-on-state-and-multi-selective-targeting/54120/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, revi...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/early-approaches-to-ras-targeting-efficacy-signals-and-known-limitations/54119/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/unmet-need-second-line-outcomes-remain-poor-for-nsclc-and-pancreatic-cancer/54118/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, revi...

CME credits: 0.75 Valid until: 29-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/ This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from ag...

CME credits: 0.75 Valid until: 28-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/ This video series focuses on translating multimodality imaging into practical care for patients with hypertrophic cardiomyopathy (HCM). Expert faculty review echocardiography, cardiac magnetic resonance, and emerging imagin...